** Cancer therapy developer Coeptis Therapeutics' COEP.O shares rise 2.3% to $11.15
** Co says it has licensed worldwide development and commercialization rights to cell therapy platform GEAR
** As part of the agreement with VyGen-Bio, Coeptis has formed a new majority-owned subsidiary, GEAR Therapeutics, to advance applications of the technology
** GEAR (Gene Edited Antibody Resistant) cell therapy platform modifies immune cells to effectively target and destroy cancer cells without being neutralized by antibodies taken during treatment
** Up to last close, COEP has risen 13.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。